COVID-19: Shionogi, final clinical trial with corona drug: S-217622
Shionogi:
Under development of oral medicine for COVID-19 treatment.
On September 28, it announced that it had started a final stage clinical trial (clinical trial) in Japan.
Drugs for Corona Patients:
The subject of administration is
A mild or asymptomatic new corona-infected person,
There is a great need for easy-to-administer drugs.
Efficacy of oral medicine:
The oral medicine developed by Shionogi “interferes with the action of enzymes necessary for virus growth.”
Take it in the early stages of infection to control the severity of the disease and relieve fever and coughing.
Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXZQOUF282PZ0Y1A920C2000000/
Shionogi starts next phase of oral COVID drug test
Japanese pharmaceutical firm Shionogi
says it has begun a new phase in a clinical trial for an orally administered coronavirus treatment.
The Osaka-based company started first-phase tests in July this year.
The firm says it found no safety problems at that stage.
In the next round of tests that started on Monday,
the company is checking the drug’s efficacy and safety by administering it once a day for five days to COVID-19 patients with mild or no symptoms.
The tests
will target hospitalized patients and those who are recovering at accommodation facilities.
Shionogi
has not disclosed the scale and duration of the trial, but it aims to be ready by the end of this year to produce the drug for one million people.
Japan’s health ministry on Monday
approved sotrovimab, made by the British pharmaceutical giant GlaxoSmithKline,
for non-severe coronavirus cases, following an earlier approval of an antibody cocktail treatment.
Neither are administered orally.
NHK WORLD-JAPAN News